Skip to main
FBLG

Fibrobiologics Inc (FBLG) Stock Forecast & Price Target

Fibrobiologics Inc (FBLG) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

FibroBiologics Inc. is focusing on the development of innovative fibroblast-based therapies that demonstrate promising advancements in wound healing and chronic disease management, underscored by positive preclinical results. The company is committed to scaling manufacturing and improving operational efficiencies, signaling a pathway for reduced production costs and streamlined regulatory processes in the clinical and commercial realms. Furthermore, the firm is progressing in key preclinical studies and manufacturing preparations for multiple investigational therapies, which showcases its potential for broad therapeutic applicability and positions it favorably within a market characterized by significant unmet medical needs.

Bears say

FibroBiologics Inc. faces significant financial challenges, highlighted by a net loss of $5.8 million for the third quarter of 2025, along with an over 80% decline in stock value year-to-date, contrasting sharply with the broader Nasdaq Biotechnology Index's 20% increase. The company's escalating research and development costs, driven by CRO, cell manufacturing, and personnel expenses, have further contributed to deepening losses, despite some efforts to implement cost-efficiency measures. Additionally, the potential failure of developmental candidates to meet commercial revenue estimates, coupled with uncertainties regarding capital resource acquisition and program development timelines, poses substantial risks to the company’s financial stability and future prospects.

Fibrobiologics Inc (FBLG) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fibrobiologics Inc (FBLG) Forecast

Analysts have given Fibrobiologics Inc (FBLG) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Fibrobiologics Inc (FBLG) has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fibrobiologics Inc (FBLG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.